|
6,217
|
| 58158 |
epithelial cell maturation
|
|
decreases_expression of
|
ANPEP
|
|
|
23608536
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
9,343
|
| 101916 |
ANPEP
|
|
affects_activity of
|
Diabetes mellitus, type II
|
|
|
23390342
|
Diabetes mellitus, type II
Insulin resistance
|
|
11,826
|
| 116860 |
SARS-CoV-2
|
NOT |
interacts (colocalizes) with
|
ANPEP
|
|
|
32015507
|
COVID-19
|
|
11,827
|
| 116864 |
SARS-CoV-2
|
NOT |
interacts (colocalizes) with
|
ANPEP
|
|
|
32142651
|
COVID-19
|
|
11,921
|
| 117263 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
in hypothalamus
|
| 117264 |
ANPEP
|
|
increases_quantity of
|
Angiotensin IV
|
in hypothalamus
|
|
8876246
|
Cardiovascular disease
|
|
12,035
|
| 118090 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
|
| 118091 |
ANPEP
|
|
increases_quantity of
|
Angiotensin IV
|
|
|
30934934
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
12,056
|
| 118329 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
|
| 118330 |
ANPEP
|
|
increases_quantity of
|
Angiotensin IV
|
|
|
19065996
|
Diabetes mellitus, type II
Insulin resistance
|
|
14,067
|
| 132958 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
|
| 132959 |
ANPEP
|
|
increases_quantity of
|
Angiotensin IV
|
|
|
33169633
|
COVID-19
|
|
14,146
|
| 133713 |
ANPEP
|
|
is_expressed_in
|
esophageal epithelium
|
|
|
24452037
|
Gastroesophageal reflux
|
|
14,159
|
| 133793 |
ANPEP
|
|
is_expressed_in
|
brain
|
|
|
23213621
|
Parkinson disease
|
|
14,205
|
| 134085 |
ANPEP
|
|
decreases_quantity of
|
Met-enkephalin
|
|
| 134086 |
ANPEP
|
|
decreases_quantity of
|
Somatostatin
|
|
| 134087 |
ANPEP
|
|
decreases_quantity of
|
Substance P (5-11)
|
|
| 134088 |
ANPEP
|
|
decreases_quantity of
|
Asn1-Angiotensin II
|
|
| 134089 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
|
| 134090 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin (2-10)
|
|
| 134091 |
ANPEP
|
NOT |
decreases_quantity of
|
Substance P
|
|
| 134092 |
ANPEP
|
NOT |
decreases_quantity of
|
Bradykinin
|
|
|
1978675
|
Cardiovascular disease
|
|
14,207
|
| 134135 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
in brain
|
|
11295571
|
Cardiovascular disease
|
|
14,224
|
| 134263 |
hyperglycemia
|
|
increases_expression of
|
ANPEP
|
|
|
23942780
|
Diabetes mellitus, type II
Insulin resistance
|
|
14,231
|
| 134368 |
ANPEP
|
|
decreases_quantity of
|
Angiotensin III
|
|
| 134369 |
ANPEP
|
|
increases_quantity of
|
Angiotensin IV
|
|
|
30978131
|
Cardiovascular disease
|
|
14,403
|
| 135923 |
ANPEP
|
|
is localized in
|
glomerular epithelium
|
|
| 135924 |
Thrombin
|
|
increases_activity of
|
ANPEP
|
in glomerular epithelial cells
|
| 135926 |
IFNG
|
|
increases_activity of
|
ANPEP
|
in glomerular epithelial cells
|
|
1354270
|
Renal
|
|
15,220
|
| 143192 |
ANPEP
|
|
is_expressed_in
|
posterior cingulate cortex
|
differentially expressed between male and female AD patients
|
|
|
Alzheimer disease
|
|
16,017
|
| 154334 |
Diabetes mellitus, type II
|
|
decreases_quantity of
|
ANPEP
|
in HDL particles
|
|
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
CIDeRplus